Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

PURPOSE: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been descr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Prébet, Thomas, Gore, Steven D., Esterni, Benjamin, Gardin, Claude, Itzykson, Raphael, Thepot, Sylvain, Dreyfus, François, Rauzy, Odile Beyne, Recher, Christian, Adès, Lionel, Quesnel, Bruno, Beach, C.L., Fenaux, Pierre, Vey, Norbert
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2011
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859209/
https://ncbi.nlm.nih.gov/pubmed/21788559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.8135
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia